Quick Answer
Aptose Biosciences Inc. reported Diluted EPS of $10.41 per share (loss) for fiscal year 2025.
Aptose Biosciences Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$10.41 | +71.4% |
| 2024 | -$36.38 | +84.0% |
| 2023 | -$227.43 | -3244.6% |
| 2022 | -$6.80 | -831.5% |
| 2021 | -$0.73 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$2.01 | +82.3% | +27.2% |
| June 30, 2025 | -$2.76 | +78.8% | -5.7% |
| March 31, 2025 | -$2.61 | +88.1% | +77.0% |
| September 30, 2024 | -$11.33 | -543.8% | +12.8% |
| June 30, 2024 | -$12.99 | -472.2% | +41.0% |
| March 31, 2024 | -$22.02 | -891.9% | -1151.1% |
| September 30, 2023 | -$1.76 | -10.7% | +22.5% |
| June 30, 2023 | -$2.27 | -32.0% | -2.3% |
- Aptose Biosciences Inc. showed an increase of +71.4% in Diluted EPS compared to the prior fiscal year.
- Over the 2021–2025 period, Aptose Biosciences Inc.’s diluted eps has declined by 1326.0% (from $0.73 per share (loss) to $10.41 per share (loss)).
- The most recent figure is from Aptose Biosciences Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 31, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: